Global Myelodysplastic Syndrome (MDS) Treatment Market by Manufacturers, Regions, Type and Application, Forecast to 2023

  • receipt Report ID : 138104
  • calendar_today Published On: Jan, 2019
  • file_copy Pages: 136
  • list Pharmaceuticals and Healthcare

Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.

Scope of the Report:

This report focuses on the Myelodysplastic Syndrome (MDS) Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050.

The worldwide market for Myelodysplastic Syndrome (MDS) Treatment is expected to grow at a CAGR of roughly 12.8% over the next five years, will reach 4560 million US$ in 2023, from 2210 million US$ in 2017, according to a new study.

Market Segment by Manufacturers, this report covers

Novartis AG

Celgene Corporation

Otsuka Pharmaceutical Co., Ltd

Sandoz Inc

Dr Reddys Laboratories Limited

Pharmascience Inc

Accord Healthcare Ltd

Mylan N.V.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Azacitidine

Lenalidomide

Decitabine

Deferasirox

Market Segment by Applications, can be divided into

Refractory cytopenia with unilineage dysplasia

Refractory anemia with ringed sideroblasts

Others

There are 15 Chapters to deeply display the global Myelodysplastic Syndrome (MDS) Treatment market.

Chapter 1, to describe Myelodysplastic Syndrome (MDS) Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Myelodysplastic Syndrome (MDS) Treatment, with sales, revenue, and price of Myelodysplastic Syndrome (MDS) Treatment, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Myelodysplastic Syndrome (MDS) Treatment, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Myelodysplastic Syndrome (MDS) Treatment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Myelodysplastic Syndrome (MDS) Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Myelodysplastic Syndrome (MDS) Treatment Introduction

1.2 Market Analysis by Type

1.2.1 Azacitidine

1.2.2 Lenalidomide

1.2.3 Decitabine

1.2.4 Deferasirox

1.3 Market Analysis by Applications

1.3.1 Refractory cytopenia with unilineage dysplasia

1.3.2 Refractory anemia with ringed sideroblasts

1.3.3 Others

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Novartis AG

2.1.1 Business Overview

2.1.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Celgene Corporation

2.2.1 Business Overview

2.2.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Otsuka Pharmaceutical Co., Ltd

2.3.1 Business Overview

2.3.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Sandoz Inc

2.4.1 Business Overview

2.4.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Dr Reddys Laboratories Limited

2.5.1 Business Overview

2.5.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Pharmascience Inc

2.6.1 Business Overview

2.6.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 Accord Healthcare Ltd

2.7.1 Business Overview

2.7.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8 Mylan N.V.

2.8.1 Business Overview

2.8.2 Myelodysplastic Syndrome (MDS) Treatment Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Myelodysplastic Syndrome (MDS) Treatment Manufacturer Market Share in 2017

3.3.2 Top 6 Myelodysplastic Syndrome (MDS) Treatment Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Myelodysplastic Syndrome (MDS) Treatment Market Analysis by Regions

4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Regions

4.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Regions (2013-2018)

4.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Regions (2013-2018)

4.2 North America Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

4.3 Europe Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

4.5 South America Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

5 North America Myelodysplastic Syndrome (MDS) Treatment by Countries

5.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries

5.1.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Countries (2013-2018)

5.1.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Countries (2013-2018)

5.2 United States Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

5.3 Canada Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

5.4 Mexico Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

6 Europe Myelodysplastic Syndrome (MDS) Treatment by Countries

6.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries

6.1.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Countries (2013-2018)

6.2 Germany Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

6.3 UK Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

6.4 France Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

6.5 Russia Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

6.6 Italy Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

7 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment by Countries

7.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Countries (2013-2018)

7.2 China Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

7.3 Japan Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

7.4 Korea Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

7.5 India Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

8 South America Myelodysplastic Syndrome (MDS) Treatment by Countries

8.1 South America Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries

8.1.1 South America Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Countries (2013-2018)

8.1.2 South America Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

8.3 Argentina Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

8.4 Colombia Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

9 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment by Countries

9.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

9.3 UAE Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

9.4 Egypt Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

9.5 Nigeria Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

9.6 South Africa Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)

10 Global Myelodysplastic Syndrome (MDS) Treatment Market Segment by Type

10.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Type (2013-2018)

10.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Type (2013-2018)

10.2 Azacitidine Sales Growth and Price

10.2.1 Global Azacitidine Sales Growth (2013-2018)

10.2.2 Global Azacitidine Price (2013-2018)

10.3 Lenalidomide Sales Growth and Price

10.3.1 Global Lenalidomide Sales Growth (2013-2018)

10.3.2 Global Lenalidomide Price (2013-2018)

10.4 Decitabine Sales Growth and Price

10.4.1 Global Decitabine Sales Growth (2013-2018)

10.4.2 Global Decitabine Price (2013-2018)

10.5 Deferasirox Sales Growth and Price

10.5.1 Global Deferasirox Sales Growth (2013-2018)

10.5.2 Global Deferasirox Price (2013-2018)

11 Global Myelodysplastic Syndrome (MDS) Treatment Market Segment by Application

11.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2013-2018)

11.2 Refractory cytopenia with unilineage dysplasia Sales Growth (2013-2018)

11.3 Refractory anemia with ringed sideroblasts Sales Growth (2013-2018)

11.4 Others Sales Growth (2013-2018)

12 Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)

12.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Growth Rate (2018-2023)

12.2 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Regions (2018-2023)

12.2.1 North America Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)

12.2.2 Europe Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)

12.2.3 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)

12.2.4 South America Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)

12.2.5 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)

12.3 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Type (2018-2023)

12.3.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Type (2018-2023)

12.3.2 Global Myelodysplastic Syndrome (MDS) Treatment Market Share Forecast by Type (2018-2023)

12.4 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Application (2018-2023)

12.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Application (2018-2023)

12.4.2 Global Myelodysplastic Syndrome (MDS) Treatment Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Myelodysplastic Syndrome (MDS) Treatment Picture

Table Product Specifications of Myelodysplastic Syndrome (MDS) Treatment

Figure Global Sales Market Share of Myelody

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery